Management of Apixaban Restart in Ongoing Gross Hematuria

Immediate Management Priorities

The American College of Cardiology recommends that anticoagulation should be discontinued in patients with active pathological hemorrhage and only restarted once adequate hemostasis is achieved, as active bleeding is an absolute contraindication to restarting therapeutic anticoagulation 1, 3
The American College of Cardiology states that anticoagulation should not resume until the urine clears and irrigation can be discontinued, with confirmation of hemostasis indicated by clear urine output without clots, stable hemoglobin without transfusion requirements, and ability to discontinue continuous bladder irrigation 1, 2

The American College of Cardiology recommends resuming apixaban 24-48 hours after achieving hemostasis and discontinuing bladder irrigation if bleeding was controlled with the three-way catheter alone, with a delay of 48-72 hours post-procedure if surgical/procedural intervention was required 1, 2
The American College of Cardiology suggests that earlier resumption (24 hours) may be reasonable after confirming adequate hemostasis if the bleeding source was identified and definitively treated 1, 2

The American College of Cardiology recommends considering pharmacological VTE prophylaxis with reduced-dose anticoagulation while awaiting hemostasis for high thrombotic risk patients, and resuming full-dose apixaban as soon as safely possible (24 hours post-hemostasis) 2, 4, 5
The American College of Cardiology advises against using bridging with parenteral anticoagulation when restarting a DOAC, as it increases bleeding risk without reducing thrombotic events 1, 2

The American College of Cardiology warns against restarting anticoagulation prematurely, as it significantly increases rebleeding risk (RR 1.91 for recurrent bleeding when anticoagulation is resumed) 1
The American College of Cardiology recommends monitoring for rebleeding after restart, with close follow-up within 1-2 weeks 2, 4